{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TNX-102+SL",
    "query": {
      "intervention": "TNX-102 SL"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 18,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TNX-102+SL&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T04:52:00.920Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03062540",
      "title": "Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "PTSD"
      ],
      "interventions": [
        {
          "name": "TNX-102 SL",
          "type": "DRUG"
        },
        {
          "name": "Placebo SL Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 358,
      "start_date": "2017-03-27",
      "completion_date": "2018-07-27",
      "has_results": true,
      "last_update_posted_date": "2024-05-22",
      "last_synced_at": "2026-09-02T04:52:00.920Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 40 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03062540"
    },
    {
      "nct_id": "NCT01903265",
      "title": "BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Primary Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "TNX-102 SL 2.8mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 205,
      "start_date": "2013-09",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2016-12-23",
      "last_synced_at": "2026-09-02T04:52:00.920Z",
      "location_count": 17,
      "location_summary": "Sacramento, California • Denver, Colorado • Brooksville, Florida + 14 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01903265"
    },
    {
      "nct_id": "NCT07464535",
      "title": "A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects (HS)"
      ],
      "interventions": [
        {
          "name": "TNX-102 SL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2022-03-18",
      "completion_date": "2022-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-09-02T04:52:00.920Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07464535"
    },
    {
      "nct_id": "NCT03110575",
      "title": "12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "PTSD"
      ],
      "interventions": [
        {
          "name": "TNX-102 SL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 190,
      "start_date": "2017-06-20",
      "completion_date": "2018-07-27",
      "has_results": true,
      "last_update_posted_date": "2025-02-06",
      "last_synced_at": "2026-09-02T04:52:00.920Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • Rogers, Arkansas • Beverly Hills, California + 28 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03110575"
    },
    {
      "nct_id": "NCT02589275",
      "title": "A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "TNX-102 SL Tablet 2.8 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 375,
      "start_date": "2015-08-04",
      "completion_date": "2016-09-28",
      "has_results": true,
      "last_update_posted_date": "2025-02-20",
      "last_synced_at": "2026-09-02T04:52:00.920Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02589275"
    },
    {
      "nct_id": "NCT03841773",
      "title": "A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "PTSD"
      ],
      "interventions": [
        {
          "name": "TNX-102 SL",
          "type": "DRUG"
        },
        {
          "name": "Placebo SL Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 192,
      "start_date": "2019-03-07",
      "completion_date": "2020-04-24",
      "has_results": true,
      "last_update_posted_date": "2025-02-06",
      "last_synced_at": "2026-09-02T04:52:00.920Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03841773"
    },
    {
      "nct_id": "NCT02436096",
      "title": "A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fibromyalgia",
        "Myofascial Pain Syndromes",
        "Muscular Diseases",
        "Musculoskeletal Diseases",
        "Nervous System Diseases",
        "Neuromuscular Diseases",
        "Rheumatic Diseases"
      ],
      "interventions": [
        {
          "name": "TNX-102 SL Tablet, 2.8mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo SL Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 519,
      "start_date": "2015-04",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-09-02T04:52:00.920Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02436096"
    },
    {
      "nct_id": "NCT06636786",
      "title": "Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Stress Reaction",
        "Acute Stress Disorder",
        "Neurocognitive Function",
        "Post-traumatic Stress"
      ],
      "interventions": [
        {
          "name": "Cyclobenzaprine HCl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 180,
      "start_date": "2025-03-25",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-09-02T04:52:00.920Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Indianapolis, Indiana • Kansas City, Kansas + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Camden",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06636786"
    },
    {
      "nct_id": "NCT07621237",
      "title": "A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Episode (MDE)",
        "Major Depressive Disorder (MDD)",
        "Depression"
      ],
      "interventions": [
        {
          "name": "TNX-102 SL",
          "type": "DRUG"
        },
        {
          "name": "Placebo sublingual tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2026-06",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-09-02T04:52:00.920Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Chino, California • Lemon Grove, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07621237"
    },
    {
      "nct_id": "NCT02829814",
      "title": "Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fibromyalgia",
        "Myofascial Pain Syndromes",
        "Muscular Diseases",
        "Nervous System Diseases",
        "Neuromuscular Diseases",
        "Rheumatic Diseases",
        "Musculoskeletal Diseases"
      ],
      "interventions": [
        {
          "name": "TNX-102 SL Tablet, 2.8 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo SL Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 51,
      "start_date": "2016-07-22",
      "completion_date": "2016-09-13",
      "has_results": true,
      "last_update_posted_date": "2025-02-25",
      "last_synced_at": "2026-09-02T04:52:00.920Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02829814"
    }
  ]
}